Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8613758

— · C

6aa70e0f-081d-507e-8a5b-824d3b6cf700

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
  • ANGIOGENESIS+0.440
  • HEDGEHOG_SIGNALING+0.430
  • APICAL_JUNCTION+0.420
  • CHOLESTEROL_HOMEOSTASIS+0.410
  • TGF_BETA_SIGNALING+0.380
  • APICAL_SURFACE+0.370
  • MYOGENESIS+0.340
  • ESTROGEN_RESPONSE_EARLY+0.310
  • HYPOXIA+0.310

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.660
  • INTERFERON_GAMMA_RESPONSE-0.550
  • ALLOGRAFT_REJECTION-0.470
  • MYC_TARGETS_V1-0.440
  • OXIDATIVE_PHOSPHORYLATION-0.430
  • DNA_REPAIR-0.340
  • E2F_TARGETS-0.330
  • IL6_JAK_STAT3_SIGNALING-0.330
  • PROTEIN_SECRETION-0.240
  • INFLAMMATORY_RESPONSE-0.220

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8613703
breast-umap@18
—D0.877
2TCGA-CV-7177-01A-11R-2016-07
head-neck@1
——0.854
3SRR8613707
breast-umap@18
—C0.851
420040084.LumA
breast-umap@18
—A0.848
5SRR8613779
breast-umap@18
—D0.830
6SRR8613716
breast-umap@18
—C0.821
7TCGA-BH-A0W4-01A-11R-A109-07
breast-umap@18
—A0.821
8TCGA-P6-A5OF-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.817
9SRR27320666
colon-landscapes@1
——0.816
10SRR9879274
lung-landscapes@6
—cohortSQ10.815

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.570Inavolisib— uncovered
ANGIOGENESIS0.440Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.430Inavolisib— uncovered
APICAL_JUNCTION0.420Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.410Remibrutinib— uncovered
TGF_BETA_SIGNALING0.380Inavolisib— uncovered
APICAL_SURFACE0.370Temsirolimus— uncovered
MYOGENESIS0.340Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.310Inavolisib— uncovered
HYPOXIA0.310Idelalisib— uncovered
UV_RESPONSE_DN0.310Inavolisib— uncovered
COAGULATION0.270Binimetinib— uncovered
MITOTIC_SPINDLE0.260Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.210Idelalisib— uncovered
NOTCH_SIGNALING0.190Inavolisib— uncovered
PANCREAS_BETA_CELLS0.190Cobimetinib— uncovered
GLYCOLYSIS0.170Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.170Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.100Inavolisib— uncovered
ANDROGEN_RESPONSE0.090Inavolisib— uncovered